Adam Feuerstein

A previous story published on Benzinga.com (subsequently unpublished) referenced a tweet by Adam Feuerstein indicating his opinion that Alkermes' drug candidate Bydureon would be approved. Bydureon has not been approved. Neither Alkermes' CEO nor the FDA have made any statement indicating if the...

TheStreet.com's Adam Feuerstein is tweeting about the Seattle Genetics (NASDAQ: SGEN) FDA meeting. Feuerstein just tweeted that the FDA panel is moving to questions and voting on Adcetris in ALCL. The FDA voted 10-0 to recommend accelerated approval of Seattle Genetics' Adcetris. Shares have...

According to Adam Feuerstein at theStreet.com, Vanda Pharmaceuticals' (NASDAQ: VNDA) first year sales of a schizophrenia drug Fanapt developed by VNDA and sold by Novartis (NYSE: NVS) totaled just $31.4 million, well below analysts' expectations. According to Feuerstein, that number is high...

Shares of Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) were down sharply right before it was halted. During the halt, Savient announced that potential bidders have passed on the company, according to Adam Feuerstein and Bloomberg. Right before the halt, shares were down $1.65 to $20.05, a loss of 7...

Adam Feuerstein, senior biotech writer at the TheStreet.com, tweeted that he thinks that Cell Therapeutics, Inc. (NASDAQ: CTIC) may buy Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS). This is all speculation on his part, and there has been no talk of a merger between the companies. Sunesis...

An update on Spherix Incorporated (NASDAQ: SPEX), which was sharply higher this morning on news that it completed a successful Phase 3 test for its diabetes drug. Well, it appears traders aren't buying it, as shares were up around 90% in pre-market trading, and are now down 18% in a dramatic...

Hello and welcome to Zing Talk, where Benzinga brings you the biggest names and brightest minds from Silicon Valley to New York City. Direct Download Subscribe in iTunes Today our guest is Adam Feuerstein, Senior Columnist and Biotech analyst for TheStreet.com. How ya doing today Adam? Good...

According to a tweet from TheStreet.com's senior biotech writer Adam Feuerstein, Sequenom, Inc. (NASDAQ: SQNM) has filed a $150 million shelf offering. Shares are down in after-hours trading on this news, losing nearly 3% to trade at $6.85. SQNM had finished the regular session at $7.05, good for a...

TheStreet.com's senior biotech columnist Adam Feuerstein had a live blog today, in which he discussed the Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) ruling from the FDA on its weight loss drug, lorcaserin. The blog had more 5,000 readers, and almost 350,000 page views, an unprecedented number of...

TheStreet.com's Adam Feuerstein tweeted that investors should not pile in on "sad-sack" story AspenBio Pharma (NASDAQ: APPY). He said that APPY = DSCO (Discovery Laboratories)(NASDAQ: DSCO).